(Reuters) - U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer.
SEATTLE—Thursday is the deadline for cities bidding to host “HQ2,” as Amazon calls its planned second headquarters, and the competition has been intense.
Business television commentator and Swiss investor Marc Faber is facing backlash for racist comments in the October edition of his "Gloom, Boom & Doom Report.
Ford Motor Co. may be both flush with cash and struggling with its stock price, but new chief executive officer Jim Hackett is in no rush to buy Wall Street's love.
As Blue Apron approaches its next earnings report in a couple of weeks, the company said Wednesday that it is laying off 6 percent of its staff as part of “a company-wide realignment of personnel to support its strategic priorities.